Profile of dupilumab and its potential in the treatment of inadequately controlled moderate-to-severe atopic dermatitis

References

• EichenfeldLFTomWLChamlinSLGuidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitisJ Am Acad Dermatol201470233835124290431
   PubMed Web of Science ®Google Scholar
• WeidingerSNovakNAtopic dermatitisLancet2016387100231109112226377142
   PubMed Web of Science ®Google Scholar
• SkabytskaYKaeslerSVolzTBiedermannTThe role of innate immune signaling in the pathogenesis of atopic dermatitis and consequences for treatmentsSemin Immunopathol2016381294326573298
   PubMed Web of Science ®Google Scholar
• DeckersIAMcLeanSLinssenSMommersMvan SchayckCPSheikhAInvestigating international time trends in the incidence and prevalence of atopic eczema 1990–2010: a systematic review of epidemiological studiesPLoS One201277e3980322808063
   PubMed Web of Science ®Google Scholar
• Mei-Yen YongATayYKAtopic dermatitis: racial and ethnic differencesDermatol Clin201735339540228577807
   PubMed Web of Science ®Google Scholar
• MargolisJSAbuabaraKBilkerWHoffstadOMargolisDJPersistence of mild to moderate atopic dermatitisJAMA Dermatol2014150659360024696036
   PubMed Web of Science ®Google Scholar
• SilverbergJIHanifinJMAdult eczema prevalence and associations with asthma and other health and demographic factors: A US population–based studyJ Allergy Clin Immunol201313251132113824094544
   PubMed Web of Science ®Google Scholar
• ShawTECurrieGPKoudelkaCWSimpsonELEczema prevalence in the United States: data from the 2003 National Survey of Children’s HealthJ Invest Dermatol20111311677320739951
   PubMed Web of Science ®Google Scholar
• SimpsonELBeiberTEckertLPatient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adultsJ Am Acad Dermatol201674349149826777100
   PubMed Web of Science ®Google Scholar
• GandhiNAPirozziGGrahamNMCommonality of the IL-4/IL-13 pathway in atopic diseaseExp Rev Clin Immunol2017135425437
   PubMed Web of Science ®Google Scholar
• GarritsenFMRoekevischEvan der SchaftJDeinumJSpulsPIde Bruin-WellerMSTen years’ experience with oral immunosuppressive treatment in adult patients with atopic dermatitis in two academic centresJ Eur Acad Dermatol Venereol201529101905191225752497
   PubMed Web of Science ®Google Scholar
• BlauveltAde Bruin-WellerMGooderhamMLong-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomized, double-blinded, placebo-controlled, phase 3 trialLancet2017389100862287230328478972
   PubMed Web of Science ®Google Scholar
• WangAXXu LandénNNew insights into T cells and their signature cytokines in atopic dermatitisIUBMB Life201567860161026178387
   PubMed Web of Science ®Google Scholar
• DharmageSCLoweAJMathesonMCBurgessJAAllenKJAbramsonMJAtopic dermatitis and the atopic march revisitedAllergy2014691172724117677
   PubMed Web of Science ®Google Scholar
• KakinumaTNakamuraKWakugawaMThymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activation-regulated chemokine level is closely related with disease activityJ Allergy Clin Immunol2001107353554111240957
   PubMed Web of Science ®Google Scholar
• HijnenDDe Bruin-WellerMOostingBSerum thymus and activation-regulated chemokine (TARC) and cutaneous T cell–attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitisJ Allergy Clin Immunol2004113233434014767451
   PubMed Web of Science ®Google Scholar
• KagamiSKakinumaTSaekiHSignificant elevation of serum levels of eotaxin-3/CCL26, but not of eotaxin-2/CCL24, in patients with atopic dermatitis: serum eotaxin-3/CCL26 levels reflect the disease activity of atopic dermatitisClin Exp Immunol2003134230931314616792
   PubMed Web of Science ®Google Scholar
• KagamiSSaekiHKomineMInterleukin-4 and interleukin-13 enhance CCL26 production in a human keratinocyte cell line, HaCaT cellsClin Exp Immunol2005141345946616045735
   PubMed Web of Science ®Google Scholar
• KaeslerSVolzTSkabytskaYToll-like receptor 2 ligands promote chronic atopic dermatitis through IL-4-mediated suppression of IL-10J Allergy Clin Immunol20141341929924698321
   PubMed Web of Science ®Google Scholar
• KimBELeungDYBoguniewiczMHowellMDLoricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6Clin Immunol2008126333233718166499
   PubMed Web of Science ®Google Scholar
• HowellMDKimBEGaoPCytokine modulation of atopic dermatitis filaggrin skin expressionJ Allergy Clin Immunol20091243 Suppl 2R7R1219720210
   PubMed Web of Science ®Google Scholar
• KamsteegMBergersMDe BoerRType 2 helper T-cell cytokines induce morphologic and molecular characteristics of atopic dermatitis in human skin equivalentAm J Pathol201117852091209921514424
   PubMed Web of Science ®Google Scholar
• SawadaEYoshidaNSugiuraAImokawaGTh1 cytokines accentuate but Th2 cytokines attenuate ceramide production in the stratum corneum of human epidermal equivalents: an implication for the disrupted barrier mechanism in atopic dermatitisJ Dermatol Sci2012681253522884781
   PubMed Web of Science ®Google Scholar
• ParkKYKimDHJeongMSLiKSeoSJChanges of antimicrobial peptides and transepidermal water loss after topical application of tacrolimus and ceramide-dominant emollient in patients with atopic dermatitisJ Korean Med Sci201025576677120436715
   PubMed Web of Science ®Google Scholar
• YamasakiKGalloRLAntimicrobial peptides in human skin diseaseEur J Dermatol2008181112118086583
   PubMed Web of Science ®Google Scholar
• LebmanDACoffmanRLInterleukin 4 causes isotype switching to IgE in T cell-stimulated clonal B cell culturesJ Exp Med198816838538623049907
   PubMed Web of Science ®Google Scholar
• BieberTAtopic dermatitisN Engl J Med2008358141483149418385500
   PubMed Web of Science ®Google Scholar
• BeckLAThaçiDHamiltonJDDupilumab treatment in adults with moderate-to-severe atopic dermatitisN Engl J Med2014371213013925006719
   PubMed Web of Science ®Google Scholar
• ThaçiDSimpsonELBeckLAEfficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trialLancet201638710013405226454361
   PubMed Web of Science ®Google Scholar
• SimpsonELBieberT1Guttman-YasskyESOLO 1 and SOLO 2 InvestigatorsTwo Phase 3 trials of dupilumab versus placebo in atopic dermatitisN Engl J Med2016375242335234827690741
   PubMed Web of Science ®Google Scholar
• BaoLZhangHChanLSThe involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitisJAKSTAT201323e2413724069552
   PubMedGoogle Scholar
• VatrellaAFabozziICalabreseCMaselliRPelaiaGDupilumab: a novel treatment for asthmaJ Asthma Allergy2014712313025214796
   PubMedGoogle Scholar
• SehraSYaoYHowellMDIL-4 regulates skin homeostasis and the predisposition toward allergic skin inflammationJ Immunol201018463186319020147633
   PubMed Web of Science ®Google Scholar
• HamiltonJDUngarBGuttman-YasskyEDrug evaluation review: dupilumab in atopic dermatitisImmunotherapy20157101043105826598956
   PubMed Web of Science ®Google Scholar
• HamiltonJDSuárez-FariñasMDhingraNDupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitisJ Allergy Clin Immunol201413461293130025482871
   PubMed Web of Science ®Google Scholar
• HeratizadehAWerfelTAnti-inflammatory therapies in atopic dermatitisAllergy201671121666167527735066
   PubMed Web of Science ®Google Scholar
• RuzickaTHanifinJMFurueMAnti–Interleukin-31 receptor a antibody for atopic dermatitisN Engl J Med2017376982683528249150
   PubMed Web of Science ®Google Scholar
• RoekevischESpulsPIKuesterDLimpensJSchmittJEfficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic reviewJ Allergy Clin Immunol2014133242943824269258
   PubMed Web of Science ®Google Scholar
• HarperJIAhmedIBarclayGCyclosporine for severe childhood atopic dermatitis: short course versus continuous therapyBr J Dermatol20001421525810651694
   PubMed Web of Science ®Google Scholar
• ZonneveldIMDe RieMABeljaardsRCThe long-term safety and efficacy of cyclosporin in severe refractory atopic dermatitis: a comparison of two dosage regimensBr J Dermatol1996135Suppl 4815208881899
   PubMed Web of Science ®Google Scholar
• GranlundHErkkoPRemitzAComparison of cyclosporin and UVAB phototherapy for intermittent one-year treatment of atopic dermatitisActa Derm Venereol2001811222711411908
   PubMed Web of Science ®Google Scholar
• HaeckIMKnolMJTen BergeOvan VelsenSGde Bruin-WellerMSBruijnzeel-KoomenCAEnteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trialJ Am Acad Dermatol20116461074108421458107
   PubMed Web of Science ®Google Scholar
• SchmittJSchakelKFolster-HolstRPrednisolone vs. cyclosporine for severe adult eczema. An investigator-initiated double-blind placebo-controlled multicenter trialBr J Dermatol2010162366166819863501
   PubMed Web of Science ®Google Scholar